参加 Global COVID-19 Vaccine Manufacturing & Supply Chain Conferences 2021!

800+
参会嘉宾
200+
参会企业和机构
50+
演讲嘉宾
20+
会下交流时间

峰会 概念

The speed with which the COVID-19 vaccine is being developed is unprecedented, and it is challenging the traditional paradigm of vaccinology science. During the COVID-19 pandemic period, scientists embarked on a race to produce safe and effective COVID-19 vaccines in record time. In less than a year, 12 vaccines have already entered clinical trials in the countries where they were approved or limited/emergency use in certain countries, 92 vaccines in clinical trials on humans, and 27 have reached the final stages of testing. At least 77 preclinical vaccines are under active investigation in animals.

Simultaneously, different stakeholders such as vaccine manufacturers and vaccine service/solution providers are working closely to ramp up COVID-19 vaccine production in order to meet the upcoming demand, with a target of up to 14 billion doses by the end of 2021. To put that figure in context, it is near twice the volume of the five billion vaccine doses of all types produced worldwide prior to the pandemic.

However, in order to vaccinate the world's population as soon as possible, additional production capacity is required. Over an 18- to 24-month period, the available global production capacity may be sufficient across all vaccine manufacturing platforms but not in a long run. In order to resolve the issue, COVID-19 vaccine manufacturers also established more than 150 partnerships with contract development and manufacturing organizations (CDMOs) to transfer technology and scale-out to increase overall production.

Also, it has become clear that many COVID-19 vaccine input supplies of raw and packaging materials, consumables, and equipment are in short supply, potentially preventing several COVID-19 vaccine manufacturers from meeting their current vaccine manufacturing commitments. For instance, the following factors have contributed to the low availability of Covid-19 vaccines in certain countries: insufficiently advanced purchasing, insufficient government investment in expanding manufacturing capacity, and insufficient coordination regarding the flow of doses from the factory to vaccination sites, information on how much is needed, and the provision of money for purchasing vaccines.

会议 议程

峰会 Global COVID-19 Vaccine Manufacturing & Supply Chain 2021 conference aims to bring together key experts and decision-makers from vaccine manufacturers, governmental organizations, regulators, non-profit organizations, and solution providers together to aid in advancements in this industry with significantly higher collaboration and implement additional short-term and sustainable solutions to the COVID-19 vaccine manufacturing & supply chain challenges.

Challenges:
  • Limited data to forecast supply and manufacturing needs for COVID-19 vaccine
  • Strategies to reduce the lengthy manufacturing timelines for COVID-19 vaccine
  • Lack of consistency and quality control for the localized vaccine manufacturing to ensure COVID-19 vaccine's quality and safety
  • Personnel and equipment that are highly specialized needed for COVID-19 vaccine manufacturing
  • Lengthy production ramp-up and technology transfer timelines
  • Lack of supply delivery of drug substances for COVID-19 vaccine production
  • Shortfalls of global collaboration network between vaccine manufacturers and CDMOs

现在注册!



Networking Package 1:

1 PASS + One 1:1 MEETING 

 

Networking Package 2:

1 PASS + THREE 1:1 MEETING 

Networking Package 3:

1 PASS + FIVE 1:1 MEETING 


限时特惠



Expires 8th August

新元 3595

SGD 5095

SGD 6995


EARLY BIRD




ExPIRES 24th SEPTEMBEr

新币3795

SGD 5295

SGD 7195


标准率

3995新元

SGD 5495

SGD 7395

现在注册

展示您的解决方案

市场 行业情报

参加 Global COVID-19 Vaccine Manufacturing & Supply Chain Conferences 2021!

注册与媒体

里玛·卡兰(Rima Karan)
市场经理

赞助与展览

Charmaine Poh
业务销售

演讲机会

钟loy
会议制作人
zh_CN简体中文
开启即时通讯
来和我们聊天吧!
你好!我怎么帮你?

请填写以下表格以接收 小册 通过电子邮件。

    感兴趣的产品*
    血液和血浆产品抗体治疗细胞治疗基因治疗蛋白质治疗学病毒疫苗免疫治疗其他生物制品非生物制剂医疗设备以上都不是

    订阅我们的邮件列表

    请填写以下表格以接收 赞助章程 通过电子邮件。

      感兴趣的产品*
      血液和血浆产品抗体治疗细胞治疗基因治疗蛋白质治疗学病毒疫苗免疫治疗其他生物制品非生物制剂医疗设备以上都不是

      订阅我们的邮件列表

      非新加坡公司, 请访问这里的注册页面。
      新加坡公司, 请访问这里的注册页面。

      请填写以下表格以接收 小册 通过电子邮件。

        感兴趣的产品*
        血液和血浆产品抗体治疗细胞治疗基因治疗蛋白质治疗学病毒疫苗免疫治疗其他生物制品非生物制剂医疗设备以上都不是

        订阅我们的邮件列表

        非新加坡公司, 请访问这里的注册页面。
        新加坡公司, 请访问这里的注册页面。

        请填写以下表格以接收您的 电子书 通过电子邮件。

          感兴趣的产品*
          血液和血浆产品抗体治疗细胞治疗基因治疗蛋白质治疗学病毒疫苗免疫治疗其他生物制品非生物制剂医疗设备以上都不是

          订阅我们的邮件列表

          请填写以下表格,通过电子邮件接收电子书。

            感兴趣的产品*
            血液和血浆产品抗体治疗细胞治疗基因治疗蛋白质治疗学病毒疫苗免疫治疗其他生物制品非生物制剂医疗设备以上都不是

            订阅我们的邮件列表

            请填写以下表格以接收此信息 电子书 通过电子邮件。

              感兴趣的产品*
              血液和血浆产品抗体治疗细胞治疗基因治疗蛋白质治疗学病毒疫苗免疫治疗其他生物制品非生物制剂医疗设备以上都不是

              订阅我们的邮件列表

              请填写以下表格以接收 小册 通过电子邮件。

                感兴趣的产品*
                血液和血浆产品抗体治疗细胞治疗基因治疗蛋白质治疗学病毒疫苗免疫治疗其他生物制品非生物制剂医疗设备以上都不是

                订阅我们的邮件列表

                请填写以下表格以接收 赞助章程 通过电子邮件。

                  感兴趣的产品*
                  血液和血浆产品抗体治疗细胞治疗基因治疗蛋白质治疗学病毒疫苗免疫治疗其他生物制品非生物制剂医疗设备以上都不是

                  订阅我们的邮件列表

                  非新加坡公司, 请访问这里的注册页面。
                  新加坡公司, 请访问这里的注册页面。